AI-Powered News Analysis•Compare coverage across the political spectrum
GoodPointsNews
Admin
Back to Dashboard
Lilly's experimental drug cuts weight by 21% in diabetes trial - reuters.com

Lilly's experimental drug cuts weight by 21% in diabetes trial - reuters.com

Lilly's experimental drug cuts weight by 21% in diabetes trial reuters.com

September 29, 2026 at 10:15 PM Original source
1 agencies covered this story

Coverage by Political Leaning

See how different sides of the spectrum reported this story

Left
0 articles
No coverage
Lean Left
0 articles
No coverage
Center
1 articles
Lean Right
0 articles
No coverage
Right
0 articles
No coverage

Key People

No people linked to this story

Locations

USA

Tags

clinical trial diabetes experimental drug lilly weight loss

All Coverage

Lilly's experimental drug cuts weight by 21% in diabetes trial - reuters.com
Reutersvia rss

<a href="https://news.google.com/rss/articles/CBMiyAFBVV95cUxOdmJvRVgxMnhYOXRRX3pwUGtKYXZic2pPbnhZTGp5SzVHbDR3M1ZQdlRkTFc2eW1NNnh3bkduWTh1MExJTXB6dTRidXNjdVBCVHJZT3lsWXJ2TWluQ2h6Rm5kTUxadFB4RzB3cUUxWFNzVmlkcmp4WXdEb2RWYy1TZkJQOFVHbGY2RnJHOHhPbjBvdmNqeFNWYmFLVkM0SzFySmo4ZTRfZ1NvN0NzRVZlMENDNlNRSlF3Y0RiREo3MzBFSGxBdDRNaA?oc=5" target="_blank">Lilly's experimental drug cuts weight by 21% in diabetes trial</a>&nbsp;&nbsp;<font color="#6f6f6f">reuters.com</font>

100%

Similar Stories

Related coverage based on topic and tags

Experimental Lilly combination drug tops Zepbound in weight-loss trial - Reuters

Experimental Lilly combination drug tops Zepbound in weight-loss trial Reuters

September 30, 2026 at 05:34 PM

Regeneron weight-loss drug halves muscle loss in combination with Novo's semaglutide in trial - reuters.com

Regeneron weight-loss drug halves muscle loss in combination with Novo's semaglutide in trial reuters.com

September 30, 2026 at 10:30 PM

Patients switching to Novo Nordisk's Wegovy pill from shots lose more weight in real-world study - Reuters

Patients switching to Novo Nordisk's Wegovy pill from shots lose more weight in real-world study Reuters

September 30, 2026 at 09:57 AM

Novo Nordisk to license experimental GLP-1 pill from China's Hengrui - Reuters

Novo Nordisk to license experimental GLP-1 pill from China's Hengrui Reuters

September 29, 2026 at 04:47 AM

Novo says Ozempic shows lower risk of cardiovascular events compared to Lilly's Mounjaro - reuters.com

Novo says Ozempic shows lower risk of cardiovascular events compared to Lilly's Mounjaro reuters.com

September 29, 2026 at 09:49 PM

US FDA approves AbbVie's drug for Parkinson's disease - reuters.com

US FDA approves AbbVie's drug for Parkinson's disease reuters.com

September 25, 2026 at 10:57 PM